Arcus Biosciences

Arcus targets the adenosine signaling axis responsible for immunosuppression in the tumor microenvironment. Its pipeline includes the anti-TIGIT antibody domvanalimab, the CD73 inhibitor quemliclustat, and the dual A2a/A2b antagonist etrumadenant. These programs are designed to block adenosine-driven immune evasion in solid tumors including lung, pancreatic, and colorectal cancers.

Under the 2020 agreement amended in 2024, Gilead holds co-development and option rights across up to 10 Arcus programs. Gilead provides clinical funding, holds an ex-U.S. commercial split on certain assets, and participates through a joint governance committee. Arcus retains full U.S. commercialization rights and creative control over Phase 2 decision-making except for assets where Gilead has exercised its options.

No. Arcus is a publicly traded clinical-stage biopharmaceutical company listed on NYSE under the ticker RCUS. It is not structured to manage family wealth or third-party capital, and its classification here likely reflects a database error. It develops its own drug candidates and funds operations through equity raises and strategic partnership payments.

The January 2024 amendment increased Gilead's equity stake from approximately 20% to 33%, added two Gilead-appointed directors to the Arcus board, and restructured the option mechanics on key programs. It deepened the joint governance framework while reaffirming Arcus's operational autonomy over U.S. rights. Analysts at the time interpreted it as a preliminary step toward a potential full acquisition of Arcus by Gilead (per Reuters, January 2024).

Arcus generates revenue through upfront payments, milestone receipts, and ongoing R&D reimbursement from the Gilead collaboration. It has no product sales. In its 2023 annual filing, the company reported $119 million in collaboration revenue and held $1.06 billion in cash and marketable securities to fund operations into 2027.

Terry Rosen serves as CEO and chairman, with Juan Jaen as president and board member. As of January 2024, the board expanded to include two Gilead appointees as part of the amended collaboration. The joint steering committee governs clinical decisions on partnered assets, but Arcus retains majority board independence and unilateral control over non-partnered pipeline activities.

Its focus on the adenosine pathway — TIGIT, CD73, and A2a/A2b targets — gives it a three-layered approach to the same immunosuppressive mechanism. The Gilead deal provides large-pharma resources without a buyout, preserving U.S. rights. Few mid-cap biotechs have one deep-pocketed corporate partner funding multiple Phase 3 programs simultaneously while leaving the biotech's own P&L and commercial rights intact in the domestic market.